A 67-year-old retired air force officer presented with a 6-month history of nonproductive cough, progressive exertional dyspnea, and weight loss. He was unable to walk beyond 100 m compared with his baseline of unlimited walking distance. He denied fever, hemoptysis, myalgia, or chest pain. He had a 30-year history of chronic plaque psoriasis with arthritis, which was managed by his dermatologist with emollients and vitamin D analogues. Joint involvement had previously been controlled with methotrexate, which was discontinued 15 years ago after resolution of his symptoms. He developed a polyarthritis flare a year ago, and adalimumab was initiated with good response.
Pulmonary function tests demonstrated a restrictive pattern with FEV 1 of 2.38 L (95% predicted), FVC of 2.73 L (78% predicted), FEV 1 /FVC ratio of 87, and diffusion capacity of 82% predicted. The patient walked 480 m on the 6-min walk test without desaturation, with a score of 7 units on the Modified Borg Dyspnea Index Scale.
High-resolution CT (HRCT) thorax scan demonstrated bilateral subpleural patchy ground glass changes of upper lobe predominance and lower lobe reticulations with traction bronchiectasis and honeycombing (Fig 2) .
CBC count with differentials, electrolyte level, creatine kinase level, and urinalysis were unremarkable. Erythrocyte sedimentation rate was 59 mm/h. Antinuclear antibody was 1:640 (homogenous pattern), and anti-double stranded DNA was 532 International Units/mL (normal < 100 International Units/mL). The remaining anti-extractable nuclear antibodies, rheumatoid factor, and anti-cyclic citrullinated peptide antibody tests were negative. Antihistone antibody was 6.1 units (positive > 1.5 units) and myositis panel were positive for anti-signal recognition particle (anti-SRP) and anti-Mi2 antibodies.
BAL showed a WBC count of 5.34 Â 10 9 cells/L, composed of 57% lymphocytes, 18% neutrophils, 22% macrophages, and 3% eosinophils. Microbiology for bacterial, mycobacterial, and fungal cultures and cytology was unremarkable.
Video-assisted thoracoscopic biopsies of the upper and lower lobes of the left lung showed a temporally and spatially homogeneous inflammatory process with relative preservation of the lung architecture and no bronchiolocentricity. The interstitium was expanded by lymphocytes. A single honeycomb space was seen in one secondary pulmonary lobule. There was focal fibrous pleurisy. No granulomas were identified (Fig 3) . What is the diagnosis? Figure 3 -Surgical lung biopsy of the left lung revealing temporally homogeneous inflammatory process with relative preservation of the lung architecture (hematoxylin and eosin stain, original magnification Â40).
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Diagnosis: Adalimumab-induced interstitial lung disease with nonspecific interstitial pneumonia pattern.
Discussion

Clinical Discussion
Adalimumab is a monoclonal human antibody against tumor necrosis factor (anti-TNF), one of many biologics that has revolutionized therapeutic options for autoimmune diseases. However, reports of immunerelated adverse events have increasingly emerged, including vasculitis, 1 lupus-like events, 2 sarcoidosis, and interstitial lung disease (ILD).
1,2
Anti-TNF-induced ILD is a recognized entity with estimated prevalence at 0.5% to 3% in treated patients. [3] [4] [5] It is a diagnosis of exclusion, with important differentials being heart failure, infectious reactivation (particularly tuberculosis), idiopathic interstitial pneumonia (IIP), connective tissue disease (CTD) with lung involvement, and exacerbation of preexisting ILD. Among the anti-TNF agents causing or worsening ILD, etanercept is most frequently implicated, followed by infliximab and adalimumab. 5 Most patients present at around 60 years of age, with female preponderance. ILD typically manifests at approximately 26 weeks after anti-TNF initiation with symptoms of dyspnea, fever, cough, and malaise, 5 as observed in the presented patient. Rheumatoid arthritis is the commonest underlying autoimmune disease reported, with previous or concomitant use of methotrexate being a significant risk factor. Spirometry usually reveals a restrictive ventilatory defect with reduced DLCO. Withdrawal of anti-TNF therapy and initiation of glucocorticoids lead to partial or complete resolution in 65% of cases. Age > 65 years, later onset of ILD from drug initiation, previous use of immunosuppression, and underlying ILD pose higher risks of mortality.
5
Having excluded infection from a negative microbiology, we had considered IIP, particularly idiopathic pulmonary fibrosis (IPF), and undifferentiated CTDassociated ILD (UCTD-ILD) and drug-induced ILD as differential diagnoses. IPF with acute exacerbation was considered because HRCT scan showed ground glass attenuation in the upper lobes on a background of radiologic features suggestive of usual interstitial pneumonia (UIP) as per the latest diagnostic criteria for IPF [6] [7] [8] in an elderly male ex-smoker.
However, his clinical and radiologic tempo were incompatible with acute exacerbation. First, fibrotic lung disease had evolved rapidly within 6 months, whereas an insidious onset would be more typical of IPF. Second, despite florid ground glass opacities, there was no associated clinical deterioration or radiographic progression after adalimumab cessation, whereas deterioration within 30 days is typical of IPF exacerbation. Finally, lymphocytosis on BAL in acute exacerbation of IPF is unusual. 9 ILD associated with psoriasis is exceedingly rare, particularly after three decades. To our knowledge, only one unpublished series of five cases reported an average time course of 5 years between onset of psoriasis and pulmonary fibrosis.
10
It is well recognized that a proportion of patients with ILD may have clinical features suggestive of an autoimmune process but may not satisfy established criteria for CTD. This entity has been described under various nomenclature, including UCTD-ILD 11 or more recently interstitial pneumonia with autoimmune features (IPAF). 12 Although IPAF has yet to be validated for clinical use, its definition has been increasingly adopted in ILD literature. The proposed diagnostic criteria are as follows: (1) presence of interstitial pneumonia on HRCT scan or surgical lung biopsy, (2) does not meet criteria of defined CTD, (3) exclusion of alternative etiologies, and (4) at least one feature from at least two of the following three domains: clinical, serologic (specific serum antibodies), or morphologic (specific HRCT scan, histopathologic patterns, or multicompartmental involvement).
This patient satisfied serologic and morphologic domains of the IPAF criteria. However, positive serologic data did not correspond to any clinical manifestations. In particular, anti-SRP and anti-Mi2 are myositis-specific antibodies rarely associated with florid ILD, 13 and there were no clinical features of dermatomyositis. Similarly, although anti-double stranded DNA is highly specific, features suggestive of systemic lupus erythematosus were lacking. Because induction of multiple, unrelated autoantibodies after anti-TNF therapy has been well described, 1,14 the absence of clinical manifestations suggested an immunologic consequence of drug therapy, rather than true CTD.
Importantly, the presence of a known inciting drug is an alternative etiology that cannot be excluded. In this case, prior pulmonary toxicity reports of anti-TNF agents,
e130 Chest Imaging and Pathology for Clinicians together with a cause-and-effect relationship demonstrated by absence of symptoms prior to drug administration, rapid onset and progression of ILD after adalimumab initiation, 1, 5 and plateau in symptoms after drug discontinuation, strongly favored the diagnosis of a drug reaction.
13,15
Radiologic Discussion HRCT scan is commonly used to delineate radiologic patterns in suspected drug-induced lung disease. ILD patterns similar to IIP have been described, with ground glass opacities most common (83%), followed by honeycombing (22%) and reticulonodular opacities (38%).
5
In evaluating fibrotic lung disease, the most important diagnostic consideration is detection of a HRCT scan pattern for UIP. According to the recent Fleischner Society White Paper criteria, 8 this is characterized by subpleural basal-predominant reticulations and peripheral traction bronchiectasis or bronchiolectasis, with honeycombing (typical UIP) or without honeycombing (probable UIP), and absence of features suggestive of an alternative diagnosis. Two other categories described include CT scan features indeterminate for UIP and CT scan features most consistent with a non-IPF diagnosis. In an elderly male patient, a UIP CT scan pattern predicts a diagnosis of IPF with high level of accuracy, 7 provided all alternative etiologies have been excluded, therefore obviating the need for a surgical lung biopsy.
In the presented patient, it may be tempting to ascribe the HRCT scan appearance to that of an acute exacerbation of IPF, suggested by abundant upper lobe ground glass opacities on a background of a typical or probable UIP pattern. 8 However, clinical-radiologic discordance, as previously explained, was inconsistent with an exacerbation. In this context, extensive ground glass opacities favored a non-IPF diagnosis, 8 supporting our decision for a surgical lung biopsy.
Pathologic Discussion
Anti-TNF agents can produce virtually any histopathologic pattern of the IIPs, with UIP (27%), nonspecific interstitial pneumonia (NSIP) (23%), and organizing pneumonia (19%) commonly reported. 5 Lymphocytosis on BAL is typical. 5 NSIP has broad differentials, with drug-induced causes, CTD, and hypersensitivity pneumonitis being more frequent than idiopathic NSIP. The presented patient had an NSIP pattern of ILD. This is characterized spatially and temporally by uniform interstitial inflammation with varying degrees of fibrosis. Pulmonary fibrosis has been reported with anti-TNF therapy. 15 Although evident on our patient's HRCT scan, it was not featured on histology, apart from a single honeycomb space which was deemed longstanding and caused by unrelated localized atelectasis. We avoided sampling lung tissue at the bases where radiologic honeycombing was already evident because features of honeycombing alone may be expected in the end stage of any inflammatory lung disease and may not necessarily be representative of the underlying interstitial pneumonia pattern. 17 The pathologic diagnosis of drug-induced ILD is challenging to make in the context of preexisting or suspected new CTD. A combination of ILD-like reactions that do not normally occur together may sometimes suggest a drug reaction. 16 However, this feature may also be seen in untreated CTD. Similarly, focal pleuritis with adhesions in our patient's lung biopsy may be found in both UCTD-ILD and some drug-induced ILD; however, absence of any clinical features of CTD rendered drug-induced NSIP the most likely culprit. Granulomas mimicking sarcoidosis have been described with anti-TNF therapy and may indicate drug-related hypersensitivity. 1 However, this was absent in the presented patient's biopsy. 1, 15, 16 Integrating clinical, radiologic, other investigation, and pathologic data is therefore imperative to arrive at a best-fit diagnosis. Table 1 18-20 summarizes distinguishing features between IPF, IPAF, and anti-TNF-induced ILD.
Histology is helpful to exclude alternative diagnoses, where a change in management may be facilitated by pathologic data. 16 Surgical lung biopsy is preferred over transbronchial biopsy because the morphologic complexity of interstitial pneumonias is frequently difficult to interpret without larger specimens afforded by a surgical biopsy. The decision for surgical biopsy must be tempered against the patient's wishes, their physiologic reserve, and the risk-benefit ratio of obtaining histology. Complications of mortality may occur in 3% to 4% of cases within 30 days postprocedure. 17 
Conclusions
In approaching a patient with new-onset ILD, the importance of a thorough medication history to elucidate possible offending etiologies and a high index of suspicion cannot be overstated. Increased pharmacovigilance is particularly timely in the era of ever-increasing biologics used to target autoimmune disease. Ultimately, drug-induced ILD is a diagnosis of exclusion, but integrating multidisciplinary expertise is paramount in diagnostic reasoning and decisionmaking, especially in situations where few therapeutic options are available.
Given the constellation of evidence to support anti-TNF-induced ILD, adalimumab was discontinued and the patient received steroids and immunosuppressant therapy, with accompanying symptomatic, physiologic, and radiologic (Fig 4) improvement.
